Photocure Partner Asieris Report the Completion of Patients Enrollment in P-III Clinical Trial of Hexvix in China
Shots:
- Photocure partner Asieris has completed patient enrollment in the P-III bridging trial of Hexvix in patients with NMIBC incl. tumors with stage carcinoma in situ (CIS), Ta, and T1. This study is being led by Peking Union Medical College Hospital and the Chinese Academy of Medical Sciences
- The purpose of the trial is to support regulatory approval of Hexvix in Mainland China & aimed at investigating the additional detection rate and safety of Hexvix and blue light cystoscopy (BLC) versus white light cystoscopy
- Asieris & Photocure ASA collaborated in Jan 2021 to obtain the exclusive registration and commercialization rights of Hexvix in mainland China and Taiwan
Ref: PRNewswire | Image: Photocure
Related News:- Asieris Reports the Completion of First Patient Dosing of Hexvix for the Treatment of Bladder Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
